← All trials
NCT00153556
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2001
- Primary completion
- —
- Completion date
- Nov 1, 2003
- First posted
- —
- Last posted
- —
- Enrollment
- 3200
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Centers for Disease Control and Prevention (CDC)Lead sponsor
- Centers for Disease Control and Prevention-Arctic Investigations ProgramOverall official - principal investigator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Alaska Native Tribal Health ConsortiumCollaborator
- Yukon Kuskokwim Health CorporationCollaborator
- Alaska State Public Health LaboratoriesCollaborator
- Centers for Disease Control and Prevention (CDC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.